Influence of Inflammatory and Oxidative Stress Pathways on Longitudinal Symptom Experiences in Children With Leukemia by Hockenberry, Marilyn J et al.
For Peer Review
Influence of Inflammatory and Oxidative Stress Pathways 
on Longitudinal Symptom Experiences in Children with 
Leukemia
Journal: Biological Research for Nursing
Manuscript ID BRN-ROR-19-01-0010.R1
Manuscript Type: Report of Original Research
Keywords: childhood leukemia, symptom trajectory, oxidative stress biomarker, inflammatory biomarker, longitudinal parallel process
 
http://mc.manuscriptcentral.com/brn
Biological Research for Nursing
For Peer Review
1
Abstract
Purpose: The purpose of this study was to explore the influence of oxidative stress (F2-
isoprostanes) and inflammatory (IL-8) biomarkers on symptom trajectories during the first 18 
months of childhood leukemia treatment.  
Method: A repeated-measures design was used to evaluate symptom experienced by 218 
children during treatment. A symptom cluster (fatigue, pain, and nausea) was explored over four 
time periods: initiation of post-induction therapy, 4 and 8 months post-induction therapy, and the 
beginning of maintenance therapy (12 months post induction). F2-isoprostanes and IL-8 were 
evaluated in cerebrospinal fluid (CSF) samples collected at the baseline (diagnosis) and then at 
the subsequent four time periods. The longitudinal relationships of theose biomarkers with the 
symptom cluster were examined using the longitudinal parallel process.
Results: Pain and fatigue levels were highest during the post-induction phases of treatment, 
and then decreased slightly during maintenance therapy; while nausea scores were relatively 
stable. Even in the later phases of treatment, children continued to experience symptoms. CSF 
levels of the biomarkers increased during the post-induction phases of treatment. Early 
increases in the biomarkers were associated with more severe symptom during the same 
period; patients who had increased biomarkers over time also experienced more severe 
symptoms over time.
Conclusions: Findings reveal that children experience symptoms throughout the course of 
leukemia treatment, and support hypothesized longitudinal relationships of oxidative stress and 
inflammatory biomarkers with symptom severity. Activation of the biomarker pathways during 
treatment may explain underlying mechanisms of symptom experiences and identify which 
children are at risk for severe symptoms.
Keywords: childhood leukemia; symptom trajectory; oxidative stress biomarker; inflammatory 
biomarker; longitudinal parallel process
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Introduction
Childhood leukemia treatment over the last three decades has resulted in survival rates 
that exceed 80% (Hunger et al., 2012; Tasian et al., 2015). Intensity of treatment required for 
cure has created numerous side-effects that often are overlooked. Fatigue, pain, nausea, 
depression, sleep disturbances, mental exhaustion and changes in activity are the most 
common treatment-related symptoms that can profoundly impact children’s lives. Up to 80% of 
children with cancer experience at least one symptom during treatment but on average children 
experience more than 10 symptoms during therapy (Baggott et al., 2012; Yeh et al., 2008). 
Treatment-related pain, nausea, and fatigue (Hedstrom et al., 2003) were the most common 
symptoms in a group of 121 children with cancer. Physical symptoms were common 
(prevalence > 35%) in a group of 160 children with cancer and included lack of energy, pain, 
drowsiness, nausea, cough, and lack of appetite (Collins et al., 2000).  Parents of cancer 
patients and health care professionals reported by proxy that cancer-related fatigue was a 
frequent symptom experienced during treatment (Gibson et al., 2005). In a study of health-
related quality of life (HRQOL) in 61 children following myelosuppressive chemotherapy, those 
with poorer functional status and higher symptom burden were associated with significant 
decreases in HRQOL; children experienced on average, 10.6 separate symptoms. The most 
common symptoms included lack of energy, pain, feeling drowsy, nausea, and feeling sad and 
irritable (Baggott et al., 2010). In a recent published study by this research team, children with 
leukemia 3 to 18 years old experienced sleep disturbance and nausea that had limited change 
over time. Fatigue, pain, and depression decreased over four time periods; however, none of 
the symptoms completely resolved over time (Hockenberry et al., 2017).
The majority of childhood cancer symptom research has been among heterogeneous 
groupings of pediatric oncology diagnoses (Hinds et al., 2007), which limits ability to tailor 
inventions for children, as specific diagnoses and treatment modalities are likely associated with 
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differing symptom profiles. There is limited understanding of the underlying mechanisms 
associated with symptom severity and why significant variations occur even when disease and 
treatment are similar. Based on our prior work, we focused on the selectedThe potential 
influence of inflammatory and oxidative stress responses during the most intensive phase of 
childhood leukemia treatment that may influence symptom toxicities and should be explored 
(Caron et al., 2009; Hockenberry et al., 2014, 2015; Moore et al., 2015, 2018; Rodgers et al., 
2016; Stenzel et al., 2010). 
IThe inflammatory pathways are is designed to clear an organism of the cause of cell 
injury (e.g. microorganisms, toxins) and the consequences of injury (e.g. necrotic cells, tissues). 
Inflammation is controlled by a host of extracellular mediators and regulators, including 
cytokines which act as key modulators of inflammation (Turner et al., 2014). IL-8 (CXCL8) is a 
critical inflammatory mediator and is elevated in many chronic inflammatory conditions found in 
adults; important examples include psoriasis, adult respiratory syndrome, chronic obstructive 
pulmonary disease, diabetes, chronic liver disease, polyarthritis, and asthma. Investigators 
report that in various cancers upregulation of IL-8 is often correlated with disease activity 
(Donnelly et al., 1993; Koch et al., 1991; Nakamura et al., 1992; Qiao et al., 2016; Zimmermann 
et al., 2011). Increased inflammatory biomarkers have also been observed in children with 
numerous illnesses such as juvenile idiopathic arthritis (Sznurkowska et al., 2018), acute kidney 
injury (Greenberg et al., 2018), and children who are maltreated (Coelho et al., 2014). IL-8 
shows recent promise as a biomarker for acute child and adolescent psychopathology (Gariup 
et al., 2015).
Oxidative stress refers to cellular injury and degeneration caused by reactive oxygen 
species (ROS). ROS are reactive because they act as an electron acceptor and “steal” 
electrons from other molecules. These compounds damage cell structures, especially lipids.  
Compared to other organs, the brain is particularly vulnerable to oxidative stress due to limited 
antioxidant capacity, greater energy requirements, and higher lipid content (Floyd, 1999). 
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Methotrexate, a drug given by multiple routes (intravenous, oral, and intrathecal) and commonly 
used for acute lymphoblastic leukemia (ALL) treatment, decreases antioxidant defense resulting 
in increased oxidative stress, and methotrexate-induced oxidative stress has been observed in 
the brain (Hockenberry et al., 2014). ROS have been linked to the pathophysiology of numerous 
disorders including traumatic brain injury, ischemia-reperfusion injury, atherosclerosis, 
inflammatory diseases, cancer, adriamycin-induced cardiomyopathy, neuro-degenerative 
conditions, and age-related functional decline (Hannun, 1996; Liou et al., 2003; Margaill et al., 
2005; Minuz et al., 2006; Montine et al., 2005; Pellegrini-Giampietro et al., 1990; Pratico et al., 
1998; Pyne-Geithman et al., 2005; Shohami et al., 1997; Weber, 1994). Two published studies 
evaluated an oxidative stress measure, total antioxidant capacity (TAC), in children with cancer. 
TAC was evaluated in 20 children with cancer at the time of diagnosis and during the first three 
cycles of chemotherapy and revealed significant decreases in TAC over time, suggesting an 
oxidative stress additive effect that could impact response to treatment, disease course, and 
prognosis (Papageorgiou et al., 2005). In another study of 13 children with leukemia and various 
solid tumors, TAC was impaired in both groups; however, higher oxidative stress occurred in the 
leukemia group (Mazor et al., 2008).   
The purpose of this study was to explore the influence of inflammatory and oxidative 
stress biomarkers on specific symptom trajectories during the first 18 months of childhood 
leukemia treatment.  Inflammatory and oxidative stress biomarkers were measured in 
cerebrospinal fluid (CSF) samples during diagnostic and therapeutic lumbar punctures at 
baseline. We hypothesized that increased levels of inflammatory and oxidative stress 
biomarkers would be associated with more severe symptom experiences during ALL treatment.
Conceptual Model
The conceptual framework for this study (Figure 1) proposed that the physiologic 
responses to leukemia treatment involve activation of inflammatory and oxidative stress 
pathways (measured by CSF biomarkers), which will influence the number and severity of 
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symptoms during childhood cancer therapy. Chemotherapy agents commonly used for 
childhood leukemia (e.g., methotrexate) can increase reactive oxygen species (ROS) production 
as a result of altered folate metabolism and decreased antioxidant enzyme production. These 
chemotherapy agents also are associated with an inflammatory response that induces cytokine 
release. A key factor underlying the organizational framework for this study is that individual 
phenotypic susceptibility to oxidative stress release and inflammatory response can contribute 
to subsequent clinical outcomes and symptom severity.
Methods
Design
A repeated-measures longitudinal design was used to evaluate treatment-related 
symptom associations experienced by 218 children and adolescents 3 to 18 years of age 
receiving ALL treatment. Symptom trajectories were explored over four time periods: initiation of 
post-induction therapy, 4 and 8 months during post-induction therapy, and the beginning of 
maintenance/continuation therapy (12 months post induction). Symptom measures included 
fatigue, pain, and nausea. Oxidative stress (F2-isoprostanes) and inflammatory (IL-8) 
biomarkers were measured in cerebrospinal fluid (CSF) samples obtained at diagnosis 
(baseline) and at four time points during ALL treatment (Times 1 through 4).
Settings and Sample
The settings for this study were four major childhood cancer treatment centers in the 
United States. When combined, the four centers diagnose more than 200 children and 
adolescents with leukemia who meet the study eligibility criteria each year. Children with a 
cognitive disability identified pre-leukemia diagnosis were ineligible for study enrollment. 
The sample size for this study was 218. All the participants provided complete 
information about sociodemographic variables (age, sex, race/ethnicity) and leukemia risk 
category. Leukemia rRisk category is determined by specific factors (biological and genetic 
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features of the leukemia cells, age, gender, and initial response to therapy) known to predict 
survival or relapse. There were intermittent, longitudinal missing data (3.7% to 28.4%) across all 
the time points among the longitudinal variables. Fortunately, Little’s (1988) missing completely 
at random (MCAR) test showed that the missing data were MCAR (2(1236) = 1223.82, p = 
.592) and did not have a negative impact on parameter estimation (Little & Rubin, 2002). Thus, 
an expectation–maximization (EM) algorithm was performed for missing data imputation on the 
two baseline biomarker measures. Baseline biomarker measurements, sociodemographic 
variables, and leukemia risk category were controlled for as covariates in the main analysis. As 
for the longitudinal missing data on the biomarkers and the symptom measures from Time 1 to 
Time 4, they were automatically handled in multilevel modeling within the two-step longitudinal 
parallel-process technique described below.
Leukemia Treatment
Children were treated on an ALL protocol. Induction therapy (1 month) included weekly 
treatment with vincristine and daunomycin (for high-risk ALL), a corticosteroid and a dose of 
Peg-asparaginase, and two intrathecal methotrexate (IT MTX) treatments (Days 1 and 29). 
Post-induction therapy (6–8 months) involved several courses of treatment that included 
asparaginase, high- or intermediate-dose intravenous (IV) MTX (depending on ALL protocol 
assignment), vincristine, doxorubicin, corticosteroid, cytarabine, and mercaptopurine. During 
post-induction IT MTX was given on Day 1 of each 12-week cycle. Throughout therapy, study 
participants received CNS prophylaxis with standardized doses of IT MTX based on 
age.  Maintenance/continuation therapy with the final study measurement, began 6 to 8 months 
after the end of induction therapy.  Time intervals for each phase of treatment were influenced 
by participants’ side effects and recovery from low blood counts.  
Data Collection
Consent was obtained from a parent or legal guardian. Children (age seven years of age 
and older) and adolescents provided assent. Symptom assessments were obtained using 
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standardized instruments and occurred during a routine follow-up clinic visit; time points were 
chosen to evaluate the most intensive phase of therapy post-induction. CSF samples were 
collected in conjunction with the lumbar puncture for IT MTX treatment that coincided most 
closely with symptom data collection.
Measures
Symptom Measures and Cluster. Based on our previous findings (Hockenberry et al., 
2017) we focused on the  3 three symptoms of fatigue, pain, and nausea. Symptoms were 
assessed using valid and reliable measures; data on each symptom was collected with a table 
PC (iPad). This study used a technological n innovative approach to symptom assessment by 
measuring each symptom using a separate reliable and validated instrument (see Table 1) with 
a tablet PC (iPad).  English and Spanish versions of the instruments were available on the tablet 
PC. Standardized measures evaluated fatigue, pain, and nausea. For consistency across 
symptoms, parent proxy was used for the 3-6-year-old age group and symptom self-report for 
children ≥ 7 years of age. Specifically, fatigue was measured by three instruments according 
toused for the different age ranges: the Child Fatigue Scale (CFS; Hinds et al., 2010) for ages 7-
12, the Adolescent Fatigue Scale (FSA; Mandrell et al., 2011) for ages 13-18, and the Parent 
Fatigue Scale (PFS; Hockenberry et al., 2003) fro ages 3-6. Then, all the scores from the three 
instruments were converted to comparable, standardized T-scores. All symptoms were reported 
over the past 2-4 weeks. Data collection required less than 25 minutes to complete at each time 
point. For each symptom scale, a higher score indicates greater symptom severity. Scores were 
used to determine symptom severity and classified into different symptom profiles labeled as 
mild, moderate and severe (see Table 1).
Because the three symptom measures (fatigue, pain, and nausea) were highly 
correlated with each other at each time point (Hockenberry et al., 2017), they were combined as 
a symptom cluster.  through exploratory factor analysis with maximum likelihood estimation 
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which returned a one-factor solution with significant factor loadings from .35 to .88 and at least 
54% of variance explained at each time point (Table 14).
CSF cytokine measures. Two milliliters of CSF were obtained in conjunction with 
diagnostic and therapeutic lumbar punctures as part of clinical treatment. CSF samples were 
placed on ice and processed within 2 hours of collection to prevent reactions such as auto-
oxidation. Samples were centrifuged at 4°C to remove any particulates, aliquoted and frozen at -
80°C, and shipped on dry ice to the core research lab for this study. IL-8 was measured using a 
cytokine-specific, AlphaLISA immunoassay kit (Perkin-Elmer) as instructed by the manufacturer. 
This is a luminescent, homogenous (no wash) proximity-based assay with extremely high 
sensitivity and a wide (4 logs) dynamic range. Each sample was assayed in triplicate wells of 
96-well, half-area white plates. Briefly, each well contained 10 µL of blank (artificial CSF with 
Prionex), sample, or standard and 20 µL of Acceptor Bead Solution.  Once the Acceptor Bead 
Solution was added to the plate, it was sealed and incubated at room temperature for 1-hour.  
After 1-hour and under low light, 20 µL of Donor Bead Solution was added to each well and 
incubated at room temperature for 30-minutes.  The plate seal was removed under low light and 
plates were read at 615 nm wavelength using a Perkin-Elmer Envision multilabel plate reader 
equipped with the Alpha option. Cytokine concentrations were determined by comparison to a 
standard curve of recombinant cytokine, using a linear regression logistic equation, and 
expressed as pg/ml. 
CSF oxidative stress measures. CSF samples for the oxidative stress biomarker were 
obtained at the same time as the cytokine samples, processed, and stored as described above. 
F2-isoprostanes (F2-IsoPs) are a sensitive non-invasive index of oxidative stress in vivo, and 
were measured by a competitive enzyme-linked immunoassay (ELISA) kit according to 
instructions (Cayman Chemical).  The kit was designed for extraction-free analysis of bodily 
fluids including CSF and has been validated for detection of 8-F2-IsoP in urine, plasma and 
other sample matrices. Briefly, each well contained 50 μl of sample or standard, 50 μl of 8-F2-
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IsoP AChE Tracer, and 50 μl of 8-F2-IsoP Antiserum. Plates were incubated for 18 hours at 4°C. 
Wells were then washed 5 times with 200 μl of wash buffer at room temperature. Ellman’s 
Reagent (200 μl) was added to each well. A Total Activity well contained only Ellman’s Reagent 
and Tracer added just before the second incubation.  A Reaction Blank contained only Ellman’s 
Reagent, and a Non-Specific Binding well contained only Tracer, added before incubation, and 
Ellman’s Reagent. Plates were covered and placed on an orbital shaker at 400rpm for 90 to 120 
min at room temperature. The plate was then read on a Perkin Elmer Envision Multi-label Plate 
Reader at 405nm. Average replicates of each standard (0.08 pg/ml to 500 pg/ml) were used to 
generate the standard curve. CSF samples were analyzed in triplicate to confirm reproducibility
Statistical Analyses
Descriptive statistics were computed for sample characteristics (sociodemographics and 
leukemia risk category) and the baseline biomarker information (Table 2) as well as the 
longitudinal variables measured from Time 1 to Time 4 (Table 3).
To test the hypothesis that participants who had increased F2-isoprostanes and IL-8 
biomarkers during the post-induction phase of treatment would experience higher severity of 
symptoms, longitudinal relationships were examined from the initiation of post-induction therapy 
(Time 1) to 4 and 8 months post-induction therapies (Times 2 & 3) to the beginning of 
maintenance/continuation therapy (Time 4), controlling for sociodemographics, leukemia risk 
category, and the baseline biomarkers. The longitudinal nature was expressed by the growth 
parameters—the initial status (or intercept) and the rate of change (or slope)—of the longitudinal 
variables.
More specifically, the longitudinal parallel process (LPP; Cheong et al., 2003), a process 
of two-step modeling, was utilized to test hypothesized longitudinal relationships. In the first 
step, the intercept and slope of each of the longitudinal variables were estimated separately by 
using univariate growth models with multilevel modeling in SAS Proc Mixed (SAS Institute, 
2011). Such separate modeling helps not only manage the unbalanced, intermittent longitudinal 
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missing data across the different longitudinal variables, but also easily control for covariates, 
such as the sociodemographic and other baseline variables, in the estimation of the intercepts 
and slopes of the longitudinal variables so that the covariates would not need to be controlled 
again in the second step. Due to its modeling flexibility, LPP is increasingly reported in the 
literature for studies with longitudinal measurements (Dowling et al., 2015; Petrou et al., 2018; 
Sousa et al., 2014; Winkler et al., 2017; Yiotaldiotariotam et al., 2013).
In the second step, structural equation modeling was employed for testing the 
longitudinal relationships between the biomarkers and symptom cluster using IBM SPSS Amos 
(Arbuckle, 2010). The structural equation model fit was evaluated using the following model-fit 
indices: chi-square of the estimated model (2), goodness of fit index (GFI), normed fit index 
(NFI), incremental fit index (IFI), relative fit index (RFI), comparative fit index (CFI), and root 
mean square error of approximation (RMSEA). A nonsignificant chi-square value (p > .05) 
suggests a good overall model fit to the data. For GFI, NFI, IFI, RFI, and CFI, values larger than 
.90 indicate that the model provides a good fit to the data, whereas RMSEA should be below 
.06. The fit indices and their criteria are commonly recommended in the literature (Hu and 
Bentler, 1999; Kline, 2005).     
Results
Descriptive Statistics
Table 2 shows that among 218 participants in the study sample, the average age was 
8.38 years (SD = 4.48). Sex was unbalanced with more boys than girls (56.0% vs. 44.0%); and 
race/ethnicity was even more unbalanced with nearly half being Hispanic (43.6%), 39.9% being 
non-Hispanic white, and much fewer being non-Hispanic black and non-Hispanic others (both 
8.3%). As for leukemia risk category, 32.6% of the participants in the study sample were at very 
high risk, 21.6% at high risk, 34.9% at average or standard risk, and 11.0% at low risk. The 
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means of the two biomarkers at baseline were 8.38 (pg/ml) (SD = 10.42) for F2-isoprostanes 
and 142.77 (pg/ml) (SD = 112.20) for IL-8.
The means and standard deviations of the longitudinal variables across the four time 
points (Table 3) demonstrate that fatigue and pain decreased over time; whereas nausea 
remained almost the same from Time 1 to Time 3 before it decreased from Time 3 to Time 4. 
Both biomarkers greatly decreased from Time 1 to Time 2 and then remained almost the same 
for the remaining time points.  
Because the three symptom measures (fatigue, pain, and nausea) were highly 
correlated with each other at each time point (Hockenberry et al., 2017), they were combined as 
a symptom cluster through exploratory factor analysis with maximum likelihood estimation which 
returned a one-factor solution with significant factor loadings from .35 to .88 and at least 54% of 
variance explained at each time point (Table 4).
Longitudinal Relationships
The model-fit indices for the initially hypothesized longitudinal relationships were 
satisfactory (2(6) = 6.12, p = .409; GFI = .99, NFI = .99, IFI = 1.00, RFI = .97, CFI = 1.00; and 
RMSEA = .010), but one path coefficient (i.e., from the intercept of F2-isoprostanes to the slope 
of symptom cluster) was not significant at the α = .10 level. To obtain a parsimonious model, the 
non-significant path coefficient was removed in the final model. Thus, a final parsimonious 
model was reached as shown in Figure 2 with the standardized estimates of path coefficients. 
The model fit indices for the parsimonious model improved and all remained satisfactory (2(7) = 
6.13, p = .525; GFI = .99, NFI = .99, IFI = 1.00, RFI = .97, CFI = 1.00; and RMSEA < .001).  
From Figure 2, we can conclude that the positive, longitudinal relationships between 
biomarkers and symptom cluster did exist in the data. Specifically, patients with an initial high 
level of both biomarkers also experienced higher severity of symptoms initially ( = .24, p < .001 
for F2-isoprostanes and  = .21, p < .001 for IL-8). For patients who had increased biomarkers 
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during the post-induction phase of treatment, they also experienced higher severity of 
symptoms over time ( = .14, p = .035 for F2-isoprostanes and  = .30, p = .015 for IL-8). In 
addition, for patients with an initial high level of IL-8, they experienced marginally higher severity 
of symptoms over time ( = .22, p = .082).  
Discussion
Pain and fatigue levels were highest during the post-induction phase of treatment (Times 
1 and 2), and then decreased slightly during maintenance therapy. This finding confirms that 
during the first few months of leukemia therapy, children experience the most intense 
symptoms. However, even at the later phase of treatment, children continued to experience 
symptoms. Nausea scores were in the mild range and relatively stable at all 4 measurement 
times consistent with the type of chemotherapy being administered for leukemia.   
Increased levels of IL-8 and F2-isoprostanes in CSF samples were found, which 
suggests that inflammatory and oxidative stress pathways are activated in response to ALL 
treatment. As hypothesized, we also found that higher levels of these CSF biomarkers were 
associated with more severe symptoms. This study continues to support the influence of 
pediatric leukemia chemotherapy drugs on ROS production as by-products of cellular toxicity. 
Evidence supports that the oxidative stress pathway is interactive and may result in significant 
cellular toxicity. The current study's findings add to the evidence that activation of the oxidative 
stress pathway can induce numerous somatic symptoms; two previous studies specifically 
evaluating biomarkers for oxidative stress also confirmed activation of the oxidative stress 
pathway during childhood cancer treatment (Mazor et al., 2008; Papageorgiou et al., 2005).
These collective findings suggest that early increases in inflammatory and oxidative 
stress may be useful in identifying which children are at greater risk of experiencing treatment-
related symptoms and in developing novel interventions to mitigate symptom severity. As 
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oxidative stress biological markers continue to be identified and described, it may be possible to 
determine individual susceptibility to oxidative stress and its influence on clinical outcomes and 
symptom severity in the future. As childhood cancer treatment continues to advance and more 
children are cured of their disease, findings from this work have the potential to allow 
individualized treatment focused on curing disease. Nursing interventions to minimize symptom 
toxicities can then be focused on the specific trajectories unique to each child with cancer.
It is worth noting that the study finding was based on only two biomarkers and three 
symptom measures. More biomarkers and more symptom measures would be interesting to be 
examined in future research for obtaining more robust results. In addition, the study finding was 
also based on a convenience sample from only four specific health systems. A larger 
randomized-cluster multi-site study on the topic in future research would be also desirable to 
provide more comprehensive evidence for informing future nursing research and practice. 
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Figure Captions
Figure 1. Biochemical mechanisms and symptoms during childhood cancer treatment.
Figure 2. The final parsimonious model of the longitudinal relationships between biomarkers 
and symptom cluster in terms of their growth parameters (intercepts and slopes) with 
standardized estimates. (†p < .10. *p < .05. **p < .01. ***p < .001).
Page 22 of 29
http://mc.manuscriptcentral.com/brn
Biological Research for Nursing
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
23
Table 1. Factor Loadings and Variance Explained in One-Factor Solution for Symptom Cluster 
at Each Time Point
Factor—Symptom Cluster
Symptom Time 1 Time 2 Time 3 Time 4
Fatigue .76 .71 .73 .88
Pain .73 .64 .72 .49
Nausea .53 .59 .56 .35
Variance Explained 63.2% 61.3% 63.2% 54.0%
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Table 1.  Symptom Measures
Severity Classification
Symptom
Instruments
Score Used in 
Data Analysis
(Scale Range) Mild Moderate Severe
Fatigue
  Child Fatigue Scale (CFS)a   
  Adolescent Fatigue Scale (FSA)b
  Parent Fatigue Scale (PFS)c
T-score of total 
score (20-80) ≤ 28
≤ 35
≤ 39
29-37
36-55
40-56
≥ 38
≥ 56
≥ 56
Pain
  Wong-Baker Faces Scaled
Raw score (1-6) ≤ 2 3-4 ≥ 5
Nausea
  Visual Analog Scale (VAS)e
Raw score (0-100) ≤ 20 30-40 ≥ 50
aHinds et al. (2010).
bMandrell et al. (2011).
cHockenberry et al. (2003).
dWong and Baker (1988).
eScott and Huskisson (1979) and Revill et al. (1976).
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Table 2. Sample Characteristics and Baseline Biomarker Information (N = 218)
Characteristic
Mean / 
Frequency (n)
SD / 
Percent (%)
Age (years) 8.38 4.48
Female 96 44.0Sex
Male 122 56.0
Hispanic 95 43.6
Non-Hispanic White 87 39.9
Non-Hispanic Black 18 8.3
Race/ Ethnicity
Non-Hispanic Other 18 8.3
Very High 71 32.6
High 47 21.6
Average/Standard 76 34.9
Leukemia Risk Category
Low 24 11.0
F2-Isoprostanes 8.38 10.42Biomarkers at Baseline (pg/ml)
IL-8 142.77 112.20
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Table 3. Means (Ms) and Standard Deviations (SDs) of the Longitudinal Variables by Time (N = 
218)
Time 1 Time 2 Time 3 Time 4Variable
(Scale Range) n M SD n M SD n M SD n M SD
Symptom Measures
Fatigue (20-80)a 195 53.92 9.98 210 49.97 10.36 196 48.20 9.10 193 46.70 8.09
Pain (1-6)b 193 2.57 2.22 207 1.66 2.15 194 1.32 1.60 191 1.29 1.80
Nausea (0-100)c 192 14.33 21.53 206 14.06 21.43 192 15.52 21.35 192 12.05 19.14
Biomarkers (pg/ml)
F2-Isoprostanes 195 7.49 8.77 209 6.36 5.17 196 6.58 7.71 194 6.66 8.42
IL-8 193 113.54 103.85 206 84.85 74.74 196 73.15 53.75 193 87.22 90.37
aMeasured using the Child Fatigue Scale (CFS; Hinds et al., 2010), the Adolescent Fatigue 
Scale (FSA; Mandrell et al., 2011), and the Parent Fatigue Scale (PFS; Hockenberry et al., 
2003). All the scores from the three instruments were converted to comparable, standardized T-
scores.
bMeasured using the Wong-Baker Faces Scale (Wong & Baker, 1988).
cMeasured using the Visual Analog Scale (VAS; Scott & Huskisson, 1979; Revill et al., 1976).
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Table 4. Factor Loadings and Variance Explained in One-Factor Solution for Symptom Cluster 
at Each Time Point
Factor—Symptom Cluster
Symptom Time 1 Time 2 Time 3 Time 4
Fatigue .76 .71 .73 .88
Pain .73 .64 .72 .49
Nausea .53 .59 .56 .35
Variance Explained 63.2% 61.3% 63.2% 54.0%
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Leukemia Treatment
Reactive Response 
Oxidative Stress Pathway
(F2-Isoprostanes) 
Reactive Response 
Inflammatory Pathway
(IL-8) 
Symptoms
(Fatigue, Pain, Nausea) 
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.24***
.14*
.21***
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